Merck, Incyte test potential first-line Keytruda combo; Mylan, Perrigo clash over Israeli listing;

@FiercePharma: Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi's Kansas City, MO plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article | Follow @CarlyHFierce

> Merck ($MRK) and Incyte ($INCY) have expanded their clinical trial collaboration to include a Phase III study combining Merck's Keytruda with Incyte's epacadostat as a first-line treatment for advanced melanoma. Release

> Mylan ($MYL) says it has no obligation to publish a prospectus in Israel for its takeover bid just because Perrigo ($PRGO) is listed on the country's stock exchange. Report

> Helsinn Healthcare and Dr. Reddy's Laboratories ($RDY) have entered into a settlement to resolve a patent fight over Helsinn's Aloxi injection in the U.S., where it is distributed by Eisai. Release

> The Drug Enforcement Agency's (DEA) attempts at stemming painkiller abuse is falling short at pharmacies. More (sub. req.)

> Chinese hospitals have reported shortages of some cheap but essential medicines thanks to alleged monopolies on raw materials. Report

> Japan's Otsuka Pharmaceutical has lost its bid for attorney fees in an Abilify patent dispute. More (reg. req.)

Medical Device News

@FierceMedDev: ICYMI yesterday: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. Article | Follow @FierceMedDev

@VarunSaxena2: Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More | Follow @VarunSaxena2

@EmilyWFierce: Report: AstraZeneca funnels billions into Dutch tax-avoidance scheme. FiercePharma story | Follow @EmilyWFierce

> Is Turing illegally thwarting generic copycats? New York antitrust squad wants to know. More

> J&J plots $10B buyback as plummeting hep C sales tarnish Q3. Article

Biotech News

@FierceBiotech: 5 experts, 1 voice: Biotech bubble? It's different this time. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Analysts, experts write off Merck's huge anacetrapib PhIII. Report | Follow @JohnCFierce

@DamianFierce: Entirely baffled by 's business model. More | Follow @DamianFierce

> Zafgen shares continue to slide on market fears. Item

> Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash. Report

> FDA misses approval date for Collegium's pain drug. News

Drug Delivery News

> Study finds EpiPens can injure children, recommends improved technique and design. More

> Russian Academy: Combining drugs with ionic liquids can up the solubility, cut polymorphism. News

> Medicines Co. enters Japanese market, handing over license to transdermal pain patch. Story

> OptiNose bags $30M in VC financing as partner Otsuka barrels toward its second PDUFA date. Article

> 3M takes on blood-brain barrier with Impel Neuropharma nasal drug delivery alliance. Report

Pharma Manufacturing News

> Pests again figure into issues in FDA warning letter to Indian API maker. More

> Cipla's new U.S. plant received Form 483 just ahead of deal. News

> CPhI report predicts growth in outsourcing for sterile injectables. More

> Aurobindo to expand India API plant fourfold. Story

> Hong Kong's gray market draws mainland Chinese looking for lifesaving meds they can't afford at home. Article

Pharma Asia News

> HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen. Story

> CIMB says Malaysian pharmas have scope to adjust to TPP changes. Report

> China's Innovent Biologics deepens pact with Eli Lilly on immuno-oncology. Article

> Japan's Astellas splashes out $300M for Immunomic's LAMP-vax platform. Item

> Hong Kong drugstores attract Chinese customers for cancer, hep C drugs. More

And Finally... Health officials and healthcare execs working to combat the rise in drug-resistant infections are training their eyes on nursing homes, where antibiotics are among the most frequently prescribed meds. More (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.